Hims & Hers Health said it will begin offering unapproved peptide treatments in November, following a U.S. policy shift. The Department of Health and Human Services issued an enforcement-discretion policy for certain compounded peptides, which the FDA has not approved for safety or effectiveness.
The initial launch, branded Peptides+, will include glutathione, NAD+ and sermorelin. Hims & Hers plans to offer other popular peptides, including BPC-157 and TB-500, later, pending further regulatory developments. The company says on its website that the treatments have not been evaluated by the FDA.
The launch expands Hims & Hers’ wellness portfolio. Its chief financial officer said revenue from the new treatments is expected to be immaterial through year-end.
The announcement coincided with the company’s third-quarter earnings report, after which its shares declined.